These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

392 related items for PubMed ID: 24528196

  • 1. Relationship of CYP3A5 genotype and ABCB1 diplotype to tacrolimus disposition in Brazilian kidney transplant patients.
    Cusinato DA, Lacchini R, Romao EA, Moysés-Neto M, Coelho EB.
    Br J Clin Pharmacol; 2014 Aug; 78(2):364-72. PubMed ID: 24528196
    [Abstract] [Full Text] [Related]

  • 2. Association of CYP3A4-392A/G, CYP3A5-6986A/G, and ABCB1-3435C/T Polymorphisms with Tacrolimus Dose, Serum Concentration, and Biochemical Parameters in Mexican Patients with Kidney Transplant.
    Alatorre-Moreno EV, Saldaña-Cruz AM, Pérez-Guerrero EE, Morán-Moguel MC, Contreras-Haro B, López-de La Mora DA, Dávalos-Rodríguez IP, Marín-Medina A, Rivera-Cameras A, Balderas-Peña LA, Gómez-Ramos JJ, Cortés-Sanabria L, Salazar-Páramo M.
    Genes (Basel); 2024 Apr 16; 15(4):. PubMed ID: 38674430
    [Abstract] [Full Text] [Related]

  • 3. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
    Staatz CE, Goodman LK, Tett SE.
    Clin Pharmacokinet; 2010 Mar 16; 49(3):141-75. PubMed ID: 20170205
    [Abstract] [Full Text] [Related]

  • 4. CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney Transplantation.
    Hu R, Barratt DT, Coller JK, Sallustio BC, Somogyi AA.
    Basic Clin Pharmacol Toxicol; 2018 Sep 16; 123(3):320-326. PubMed ID: 29603629
    [Abstract] [Full Text] [Related]

  • 5. Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients.
    Cho JH, Yoon YD, Park JY, Song EJ, Choi JY, Yoon SH, Park SH, Kim YL, Kim CD.
    Transplant Proc; 2012 Jan 16; 44(1):109-14. PubMed ID: 22310591
    [Abstract] [Full Text] [Related]

  • 6. Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients.
    Santoro A, Felipe CR, Tedesco-Silva H, Medina-Pestana JO, Struchiner CJ, Ojopi EB, Suarez-Kurtz G.
    Pharmacogenomics; 2011 Sep 16; 12(9):1293-303. PubMed ID: 21806386
    [Abstract] [Full Text] [Related]

  • 7. ABCB1 haplotype influences the sirolimus dose requirements in Chinese renal transplant recipients.
    Lee J, Huang H, Chen Y, Lu X.
    Biopharm Drug Dispos; 2014 Apr 16; 35(3):164-72. PubMed ID: 24285256
    [Abstract] [Full Text] [Related]

  • 8. Influence of the CYP3A4/5 genetic score and ABCB1 polymorphisms on tacrolimus exposure and renal function in Brazilian kidney transplant patients.
    Genvigir FD, Salgado PC, Felipe CR, Luo EY, Alves C, Cerda A, Tedesco-Silva H, Medina-Pestana JO, Oliveira N, Rodrigues AC, Doi SQ, Hirata MH, Hirata RD.
    Pharmacogenet Genomics; 2016 Oct 16; 26(10):462-72. PubMed ID: 27434656
    [Abstract] [Full Text] [Related]

  • 9. Population pharmacokinetic analysis and dosing guidelines for tacrolimus co-administration with Wuzhi capsule in Chinese renal transplant recipients.
    Jing Y, Kong Y, Hou X, Liu H, Fu Q, Jiao Z, Peng H, Wei X.
    J Clin Pharm Ther; 2021 Aug 16; 46(4):1117-1128. PubMed ID: 33768546
    [Abstract] [Full Text] [Related]

  • 10. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.
    Ogasawara K, Chitnis SD, Gohh RY, Christians U, Akhlaghi F.
    Clin Pharmacokinet; 2013 Sep 16; 52(9):751-62. PubMed ID: 23633119
    [Abstract] [Full Text] [Related]

  • 11. Effect of CYP3A5 and ABCB1 Gene Polymorphisms on Tacrolimus Blood Concentration in Renal Transplant Recipients.
    Yildirim E, Şahin G, Kaltuş Z, Çolak E.
    Clin Lab; 2019 Nov 01; 65(11):. PubMed ID: 31710427
    [Abstract] [Full Text] [Related]

  • 12. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.
    Jun KR, Lee W, Jang MS, Chun S, Song GW, Park KT, Lee SG, Han DJ, Kang C, Cho DY, Kim JQ, Min WK.
    Transplantation; 2009 Apr 27; 87(8):1225-31. PubMed ID: 19384171
    [Abstract] [Full Text] [Related]

  • 13. Effect of ABCB1 diplotype on tacrolimus disposition in renal recipients depends on CYP3A5 and CYP3A4 genotype.
    Vanhove T, Annaert P, Lambrechts D, Kuypers DRJ.
    Pharmacogenomics J; 2017 Dec 27; 17(6):556-562. PubMed ID: 27378609
    [Abstract] [Full Text] [Related]

  • 14. Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms.
    Op den Buijsch RA, Christiaans MH, Stolk LM, de Vries JE, Cheung CY, Undre NA, van Hooff JP, van Dieijen-Visser MP, Bekers O.
    Fundam Clin Pharmacol; 2007 Aug 27; 21(4):427-35. PubMed ID: 17635182
    [Abstract] [Full Text] [Related]

  • 15. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.
    Elens L, Bouamar R, Hesselink DA, Haufroid V, van der Heiden IP, van Gelder T, van Schaik RH.
    Clin Chem; 2011 Nov 27; 57(11):1574-83. PubMed ID: 21903774
    [Abstract] [Full Text] [Related]

  • 16. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.
    Shi XJ, Geng F, Jiao Z, Cui XY, Qiu XY, Zhong MK.
    J Clin Pharm Ther; 2011 Oct 27; 36(5):614-24. PubMed ID: 21916909
    [Abstract] [Full Text] [Related]

  • 17. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
    Staatz CE, Goodman LK, Tett SE.
    Clin Pharmacokinet; 2010 Apr 27; 49(4):207-21. PubMed ID: 20214406
    [Abstract] [Full Text] [Related]

  • 18. CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III).
    Yoon SH, Cho JH, Kwon O, Choi JY, Park SH, Kim YL, Yoon YR, Won DI, Kim CD.
    Transplantation; 2013 Mar 27; 95(6):828-34. PubMed ID: 23364483
    [Abstract] [Full Text] [Related]

  • 19. Impact of the CYP3A5 genotype on the distributions of dose-adjusted trough concentrations and incidence of rejection in Japanese renal transplant recipients receiving different tacrolimus formulations.
    Niioka T, Kagaya H, Saito M, Inoue T, Numakura K, Yamamoto R, Habuchi T, Satoh S, Miura M.
    Clin Exp Nephrol; 2017 Oct 27; 21(5):787-796. PubMed ID: 28271256
    [Abstract] [Full Text] [Related]

  • 20. Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients.
    Provenzani A, Notarbartolo M, Labbozzetta M, Poma P, Vizzini G, Salis P, Caccamo C, Bertani T, Palazzo U, Polidori P, Gridelli B, D'Alessandro N.
    Int J Mol Med; 2011 Dec 27; 28(6):1093-102. PubMed ID: 21922127
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.